摘要
目的:探讨不同剂量重组人生长激素(recombinant human growth hormone,rh GH)联合小剂量司坦唑醇治疗非生长激素缺乏性矮小症患儿的临床效果。方法:选取2017年1月至2018年1月河北大学附属医院收治的非生长激素缺乏性矮小症患儿99例,按照随机数字表法分为A、B及C组,每组33例。A组患儿给予小剂量司坦唑醇治疗,B组患儿在A组的基础上联合小剂量rh GH治疗,C组患儿在A组的基础上联合大剂量rh GH治疗。连续治疗1年后对三组患儿的临床疗效,治疗前后的身高、生长速率(GV)、身高标准差(Ht SDS)、骨龄增加值(ΔBA)、身高年龄增加值(ΔHA)、ΔHA/ΔBA及不良反应发生率等指标进行比较。结果:A、B及C组患儿的总有效率为69.70%(23/33)、81.82%(27/33)及93.94%(31/33),三组间比较,差异有统计学意义(P <0.05)。治疗后,A、B及C组患儿身高、GV及Ht SDS均较治疗前明显升高,且C组患儿明显高于B组,B组患儿明显高于A组,三组间比较,差异有统计学意义(P <0.05)。治疗后,三组患儿的ΔBA、ΔHA及ΔHA/ΔBA比较,差异均无统计学意义(P> 0.05)。治疗期间,A、B及C组患儿的不良反应发生率分别为6.06%(2/33)、12.12%(4/33)及15.15%(5/33),组间比较,差异无统计学意义(P> 0.05)。结论:rh GH联合小剂量司坦唑醇治疗非生长激素缺乏性矮小患儿症的疗效显著,可迅速提高患儿的GV和身高,且大剂量rh GH联合小剂量司坦唑醇的效果更为显著。rh GH的应用不加速患儿的骨骼成熟,不影响患儿的生长潜能,且治疗安全性良好。
OBJECTIVE: To probe into the clinical effect of different doses of recombinant human growth hormone( rh GH) combined with small dose of stanozolol in the treatment of non-growth hormone deficient dwarfism. METHODS:Totally 99 children with non-growth hormone deficient dwarfism admitted into the Affiliated Hospital of Hebei University from Jan. 2017 to Jan. 2018 were selected and divided into group A,group B and group C via random number table,with 33 cases in each group. Group A was treated with small dose of stanozolol,group B was given small dose of rhGH based on group A,while group C was given large dose of rhGH based on group A. The clinical efficacy after 1-year treatment,height( Ht) before and after treatment,growth velocity( GV),height standard deviations( Ht SDS),increment of bone age( ΔBA),increment of height age( ΔHA),ΔHA/ΔBA and incidences of adverse drug reactions were compared among three groups. RESULTS: The total effective rates of group A,group B and group C were respectively 69. 70%( 23/33),81. 82%( 27/33) and 93. 94%( 31/33),with statistically significant differences( P < 0. 05). After treatment,the Ht,GV and Ht SDS of three groups were significantly increased,those of group C were significantly higher than those of group B,and those of group B were significantly higher than those of group A,with statistically significant differences( P < 0. 05). After treatment,there were no statistical significance in differences in ΔBA,ΔHA and ΔHA/ΔBA among three groups( P > 0. 05). During treatment,the incidences of adverse drug reactions of group A,group B and group C were respectively 6. 06%( 2/33),12. 12%( 4/33) and15. 15%( 5/33),the differences among groups were not statistically significant( P > 0. 05). CONCLUSIONS: The efficacy of rhGH combined with small dose of stanozolol in the treatment of non-growth hormone deficient dwarfism in children is remarkable,which can rapidly improve the GV and height of children,and the combination of large-dose rhGH with small-dose stanozolol is more effective. rh GH does not accelerate skeletal maturation,does not affect the growth potential,and has a good therapeutic safety.
作者
魏倩
解欣
王玉
WEI Qian;XIE Xin;WANG Yu(Dept.of Pediatrics,Affiliated Hospital of Hebei University,Hebei Baoding 071000,China;College of Medicine,Hebei University,Hebei Baoding 071000,China)
出处
《中国医院用药评价与分析》
2021年第6期654-657,共4页
Evaluation and Analysis of Drug-use in Hospitals of China
基金
2019年度河北省医学科学研究课题计划(No.20190938)。
关键词
非生长激素缺乏性矮小症
司坦唑醇
重组人生长激素
不同剂量
临床疗效
生长速率
Non growth hormone deficiency dwarfism
Stanozolol
Recombinant human growth hormone
Different doses
Clinical efficacy
Growth rate
